title: [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
authors.forename: L
authors.initials: L
authors.lastname: Cardozo
authors.forename: M
authors.initials: M
authors.lastname: Lisec
authors.forename: R
authors.initials: R
authors.lastname: Milard
authors.forename: O
authors.initials: O
authors.lastname: Van Vierssen Trip
authors.forename: I
authors.initials: I
authors.lastname: Kuzmin
authors.forename: T E
authors.initials: TE
authors.lastname: Drogendijk
authors.forename: A M
authors.initials: AM
authors.lastname: Huang
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011812:Quinuclidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000378:metabolism; D014554:Urination / Q000187:drug effects
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate